Clinical Trials in Degenerative Diseases

REVIEW
Year
: 2019  |  Volume : 4  |  Issue : 2  |  Page : 37--42

Clinical progress of cell therapy in treating age-related macular degeneration


Ling Diao1, Pan-Feng Fang2 
1 Institute of Burn Research, Wuxi Third People's Hospital, Wuxi, Jiangsu Province, China
2 Eyecure Therapeutics Inc. (Jiangsu), Wuxi, Jiangsu Province, China

Correspondence Address:
Ling Diao
Institute of Burn Research, Wuxi Third People's Hospital, Wuxi, Jiangsu Province
China
Pan-Feng Fang
Eyecure Therapeutics Inc. (Jiangsu), Wuxi, Jiangsu Province
China

Age-related macular degeneration is a retinal degenerative lesion caused by cell atrophy and dysfunction of retinal pigment epithelium. The degeneration of retinal pigment epithelium cells further leads to the apoptosis of photoreceptor cells, causes vision deterioration and eventually even blindness. Age-related macular degeneration is one of the top three retinal diseases causing blindness in the world. In recent years, exogenous retinal pigment epithelium cell therapy has emerged as a breakthrough treatment for age-related macular degeneration disease. In this review, we will briefly introduce the policies and regulations of cell therapy and discuss the clinical progress in the treatment of age-related macular degeneration using retinal pigment epithelium cells.


How to cite this article:
Diao L, Fang PF. Clinical progress of cell therapy in treating age-related macular degeneration.Clin Trials Degener Dis 2019;4:37-42


How to cite this URL:
Diao L, Fang PF. Clinical progress of cell therapy in treating age-related macular degeneration. Clin Trials Degener Dis [serial online] 2019 [cited 2019 Sep 15 ];4:37-42
Available from: http://www.clinicaltdd.com/article.asp?issn=2542-3975;year=2019;volume=4;issue=2;spage=37;epage=42;aulast=Diao;type=0